구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TCR-like CAR-T (TCR-like CAR-T) PersonGen BioTherapeutics (Suzhou)…·Safety and Efficacy of TCR-like CA… 9 trials |
|---|---|
Overview Program | TCR-like CAR-T |
Overview Company | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
Overview Modality | CGT |
Overview Target | Safety and Efficacy of TCR-like CAR-T |
Overview Indication | Safety and Efficacy of TCR-like CAR-T |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | A novel nanobody-based TCR-like CAR-T therapy targeting PRAME for the treatment of acute myeloid leukemia.. Chimeric antigen receptor (CAR) T-cell immunotherapy in acute myeloid leukemia (AML) remains challenging due to the lack of specific cell surface antigens that are highly expressed on leukemic blasts but largely absent in hematopoietic stem/progenitor cells (HSPCs) and healthy tissues. Targe… |
Toxicology CRS | Reported |
Clinical Safety signal | A novel nanobody-based TCR-like CAR-T therapy targeting PRAME for the treatment of acute myeloid leukemia.. Chimeric antigen receptor (CAR) T-cell immunotherapy in acute myeloid leukemia (AML) remains challenging due to the lack of specific cell surface antigens that are highly expressed on leukemic blasts but largely absent in hematopoietic stem/progenitor cells (HSPCs) and healthy tissues. Targe… |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TCR-like CAR-T (TCR-like CAR-T) PersonGen BioTherapeutics (Suzhou)…·Safety and Efficacy of TCR-like CA… 9 trials |
|---|---|
Overview Program | TCR-like CAR-T |
Overview Company | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
Overview Modality | CGT |
Overview Target | Safety and Efficacy of TCR-like CAR-T |
Overview Indication | Safety and Efficacy of TCR-like CAR-T |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | A novel nanobody-based TCR-like CAR-T therapy targeting PRAME for the treatment of acute myeloid leukemia.. Chimeric antigen receptor (CAR) T-cell immunotherapy in acute myeloid leukemia (AML) remains challenging due to the lack of specific cell surface antigens that are highly expressed on leukemic blasts but largely absent in hematopoietic stem/progenitor cells (HSPCs) and healthy tissues. Targe… |
Toxicology CRS | Reported |
Clinical Safety signal | A novel nanobody-based TCR-like CAR-T therapy targeting PRAME for the treatment of acute myeloid leukemia.. Chimeric antigen receptor (CAR) T-cell immunotherapy in acute myeloid leukemia (AML) remains challenging due to the lack of specific cell surface antigens that are highly expressed on leukemic blasts but largely absent in hematopoietic stem/progenitor cells (HSPCs) and healthy tissues. Targe… |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교